AMGEN

US Value & Access

Amgen Inc.
One Amgen Center Drive
Thousand Oaks, CA 91320-1799
www.amgen.com

July 2nd, 2021

To: The Office of the Attorney General of Vermont

Via: Electronic Mail (AGO.DrugCosts@vermont.gov; AGO.highcostprescriptiondrugs@vermont.gov)

Re: Notice of New Drug Introduction Pursuant to 18 V.S.A. § 4637 (c)

On June 3rd, 2021 and pursuant to 18 V.S.A. § 4637 (b), Amgen Inc, USA (Amgen) submitted a notice of new drug introduction for the following:

Name of New Prescription Drug	NDC Number	Date of Commercial Availability	WAC
LUMAKRAS™ (30-day supply, 1 bottle of 240 120mg tablets)	55513-0488-24	June 3rd, 2021	$17,900.00

Amgen now provides the following additional information pursuant 18 V.S.A § 4637 (c):

1. United States and international marketing and pricing plans used at launch
   - This information is not in the public domain. 18 V.S.A. §4637(d)
2. Estimate Volume of Patients:
   - This information is not in the public domain. 18 V.S.A. §4637(d)
3. Whether the FDA granted breakthrough therapy designation or priority review:
   - FDA did grant breakthrough designation and priority review for LUMAKRAS.
4. Date and price of acquisition:
   - Not Applicable

Amgen provides this report consistent with its understanding and interpretation of 18 V.S.A § 4637 and its provisions. In providing this report, Amgen does not waive any rights it may have at law or in equity with respect to 18 V.S.A. § 4637, its interpretation, and/or its application to Amgen or any of its affiliates, now or in the future. Amgen, on behalf of itself and its affiliates, expressly reserves all such rights.

Regards,

Pat Costello

Executive Director, US Value and Access Strategy

Amgen Inc, USA